Leonard Frank X 4
4 · NovoCure Ltd · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
NovoCure (NVCR) CEO Leonard Frank X Buys 1,905 Shares via ESPP
What Happened
- Leonard Frank X, CEO of NovoCure Ltd (NVCR), acquired 1,905 ordinary shares on 2026-06-30. The shares were purchased at $11.15 per share for a total reported value of $21,241. The transaction is reported as an acquisition (Transaction Code A).
Key Details
- Transaction date: 2026-06-30; Form 4 filed: 2026-07-01 (timely filing).
- Price and amount: 1,905 shares at $11.15 per share; total = $21,241.
- Plan: Shares were purchased under the 2025 NovoCure Employee Share Purchase Plan (ESPP).
- Purchase mechanics: Price was set at 85% of the closing price of NovoCure ordinary shares on 2026-01-01 (per filing footnote).
- Exemptions: The transaction is reported as exempt under Rule 16b-3(c) (per footnote).
- Shares owned after the transaction: not specified in the provided filing.
Context
- This was an ESPP purchase — a routine employee benefit that results in the insider acquiring company stock at a discount. Purchases can be interpreted differently by investors, but ESPP transactions are commonly recurring and structured by plan terms rather than discretionary open-market timing.
Insider Transaction Report
Form 4
NovoCure LtdNVCR
Leonard Frank X
Chief Executive Officer
Transactions
- Award
Ordinary Shares
[F1][F2]2026-06-30$11.15/sh+1,905$21,241→ 461,425 total
Footnotes (2)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
- [F2]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Signature
Steven Robbins, as attorney in fact for Leonard, Frank X.|2026-07-01